STOCK TITAN

PINEAPPLE EXPRES CANNABIS - PNXP STOCK NEWS

Welcome to our dedicated page for PINEAPPLE EXPRES CANNABIS news (Ticker: PNXP), a resource for investors and traders seeking the latest updates and insights on PINEAPPLE EXPRES CANNABIS stock.

Pineapple Express Cannabis (PNXP) is a leading player in the cannabis industry, focusing on cultivation, production, and distribution of high-quality cannabis products. With a strong presence in metro Los Angeles, the company has recently signed agreements to manage 9 additional dispensaries, further solidifying its position in the market. Pineapple Express Cannabis boasts a diverse range of products and a growing customer base, supported by strategic partnerships and a commitment to innovation.

Rhea-AI Summary

Pineapple Consolidated, Inc. (PCI), a 25% minority-owned asset of Pineapple Express Cannabis Company (OTC: PNXP), faces a lawsuit from rapper 2 Chainz over his investment in PCI's Hollywood cannabis dispensary. The lawsuit comes after the dispensary's temporary closure in late July and throughout August. PCI is working to resolve the issue through private arbitration, as stipulated in their agreement with 2 Chainz's investment group.

The temporary closure is due to a court-ordered restructuring of ownership, involving the removal of a social equity partner. This precautionary measure ensures compliance with local cannabis regulations during the ownership transition. The Hollywood dispensary is set to relaunch on September 1st, fully compliant with local and state laws.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Pineapple Express Cannabis Company (OTC: PNXP) has signed a significant revenue-generating contract through its subsidiary, Ananas Growth Ventures (AGV), with Pineapple Consolidated to receive 50% of management fee revenue from multiple cannabis dispensaries in Los Angeles.

This agreement includes seven retail locations in key areas such as Hollywood, Venice Blvd., Van Nuys, Echo Park, Ventura Blvd., Northridge, and Beverly Grove. The deal is effective from April 20, 2024, and was ratified on June 10, 2024. In exchange, AGV has issued a $5 million promissory note with 1% annual interest, payable by April 20, 2029.

CEO Matthew Feinstein emphasized that this move is important for the company's sustainable and profitable growth, particularly in light of the impending cannabis rescheduling in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Pineapple Express Cannabis Company (PNXP) celebrates its 2-Year anniversary at its Hollywood dispensary with celebrity backers, state-of-the-art features, and aggressive expansion plans. The resolved partnership dispute and the appointment of a new CEO signal positive growth for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Pineapple Express Cannabis Company has announced the licensing, leasehold, and development of 9 additional retail dispensary locations in Los Angeles. The company's 50% owned asset, Pineapple Consolidated Inc., will manage the dispensaries. Once all 10 stores are operational, Pineapple Express aims to become the largest retail brand in Southern California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Pineapple Express Cannabis Company has started managing and operating its flagship dispensary, named 'Pineapple Express Hollywood,' located at 1708 Vine Street in Hollywood, CA. This is the first of 10 stores planned for development in metro Los Angeles by Pineapple Consolidated Inc., a 50% owned asset of the Company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Pineapple Express Cannabis Company is seeking to raise $5 million from accredited investors through the offering of 5 million shares of its common stock at $1 per share. The funds will be used to launch 10 fully licensed retail cannabis dispensaries in the metro Los Angeles area and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of PINEAPPLE EXPRES CANNABIS (PNXP)?

The current stock price of PINEAPPLE EXPRES CANNABIS (PNXP) is $0.99 as of July 31, 2024.

What is the market cap of PINEAPPLE EXPRES CANNABIS (PNXP)?

The market cap of PINEAPPLE EXPRES CANNABIS (PNXP) is approximately 3.2M.

What is Pineapple Express Cannabis known for?

Pineapple Express Cannabis is known for its focus on cultivation, production, and distribution of high-quality cannabis products.

Where does Pineapple Express Cannabis have a strong presence?

Pineapple Express Cannabis has a strong presence in metro Los Angeles.

What recent agreements has Pineapple Express Cannabis signed?

Pineapple Express Cannabis has recently signed agreements to manage 9 additional dispensaries in metro Los Angeles.

What sets Pineapple Express Cannabis apart in the market?

Pineapple Express Cannabis stands out in the market due to its diverse range of products, growing customer base, strategic partnerships, and commitment to innovation.

Who is the CEO of Pineapple Express Cannabis?

Matthew Feinstein serves as the CEO, President, and Interim CFO of Pineapple Express Cannabis.

How can I contact Pineapple Express Cannabis?

You can reach Pineapple Express Cannabis at 888-245-5703.

What is the ownership structure of Pineapple Express Cannabis?

The company holds equity in all the dispensaries it manages.

What is the core focus of Pineapple Express Cannabis?

The core focus of Pineapple Express Cannabis is on cultivating, producing, and distributing high-quality cannabis products.

What geographical area does Pineapple Express Cannabis operate in?

Pineapple Express Cannabis operates primarily in metro Los Angeles.

What distinguishes Pineapple Express Cannabis in the cannabis industry?

Pineapple Express Cannabis is distinguished by its product range, customer base, partnerships, and innovation efforts.

PINEAPPLE EXPRES CANNABIS

OTC:PNXP

PNXP Rankings

PNXP Stock Data

3.18M
1.83M
90.75%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Los Angeles